Article citationsMore>>
Banerji, U., van Herpen, C.M.L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I.R., Boni, V., Rolfo, C., de Vries, E.G.E., Rottey, S., Geenen, J., Eskens, F., Gil-Martin, M., Mommers, E.C., Koper, N.P. and Aftimos, P. (2019) Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. The Lancet Oncology, 20, 1124-1135.
https://doi.org/10.1016/S1470-2045(19)30328-6
has been cited by the following article:
-
TITLE:
Antibody-Coupled Drugs in HER2-Positive Gastric Cancer
AUTHORS:
Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian
KEYWORDS:
Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.7,
July
7,
2023
ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.
Related Articles:
-
Philippe Chassy
-
Basem Battah, Jumana Saleh, Marroan Bachour, Maher Salamoon
-
M. Charfeddine, Malek Gassoumi, H. Mosbahi, C. Gaquiére, M. A. Zaidi, H. Maaref
-
Erdmann Görg
-
Gael Kietga, Wilfried Mosse, Patricia Agbanglanon, Bertrand Compaore, Davy Nchepo, Evrard Seka, Sanae Elmajjaoui, Hanane Elkacemi, Tayeb Kebdani, Amine Lachgar, Noureddine Benjaafar